{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Antagonists&page=2", "query": { "condition": "Hormone Antagonists", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Antagonists&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T13:30:11.975Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04460872", "title": "Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injury", "Spinal Cord Injuries", "Trauma, Nervous System", "Wounds and Injury", "Central Nervous System Diseases", "Spinal Cord Diseases", "Gonadal Disorders", "Endocrine System Diseases", "Hypogonadism", "Genital Diseases, Male", "Spinal Cord Trauma", "Injuries, Spinal Cord", "Walking, Difficulty", "Gait Disorders, Neurologic", "Locomotion Disorder, Neurologic", "Wounds and Injuries", "Nervous System Diseases", "Testosterone Deficiency", "Androgen Deficiency", "Hormone Deficiency" ], "interventions": [ { "name": "Testosterone Enanthate", "type": "DRUG" }, { "name": "Locomotor Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "North Florida Foundation for Research and Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "2021-01-31", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 2, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460872" }, { "nct_id": "NCT04711252", "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "AZD9833 placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1370, "start_date": "2021-01-28", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 30, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Harbor City", "state": "California" }, { "city": "Solvang", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711252" }, { "nct_id": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "AZD9833 Placebo", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Letrozole placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 315, "start_date": "2021-06-30", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 64, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964934" }, { "nct_id": "NCT06801236", "title": "Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer (Adenocarcinoma)", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "ACE-232 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerand Therapeutics (Hong Kong) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 67, "start_date": "2025-05-12", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 8, "location_summary": "La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06801236" }, { "nct_id": "NCT01410799", "title": "Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Deficiency", "Aging" ], "interventions": [ { "name": "Growth Hormone Releasing Hormone (GHRH )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 13, "start_date": "2011-05", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2019-05-24", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410799" }, { "nct_id": "NCT06584916", "title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 376, "start_date": "2024-09-13", "completion_date": "2025-11-21", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pelham", "state": "Alabama" }, { "city": "Santa Ana", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06584916" }, { "nct_id": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced Breast Cancer" ], "interventions": [ { "name": "ETX-636 dose escalation", "type": "DRUG" }, { "name": "ETX-636 dose escalation in combination with fulvestrant", "type": "DRUG" }, { "name": "ETX-636 dose expansion in combination with fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ensem Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2025-06-10", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 10, "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06993844" }, { "nct_id": "NCT02472275", "title": "PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage I Prostate Adenocarcinoma", "Stage II Prostate Adenocarcinoma", "Stage III Prostate Adenocarcinoma" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Multitargeted Tyrosine Kinase Inhibitor PLX3397", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2015-06", "completion_date": "2019-08-05", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 3, "location_summary": "Detroit, Michigan • Petoskey, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02472275" }, { "nct_id": "NCT05697809", "title": "Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "OXU-001", "type": "DRUG" }, { "name": "Semi-automated suprachoroidal illuminated microcatheter", "type": "DEVICE" }, { "name": "Ozurdex® Ophthalmic Intravitreal Implant", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Oxular Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-08-07", "completion_date": "2024-12-05", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Oak Forest", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05697809" }, { "nct_id": "NCT01008410", "title": "Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Proctitis", "Proctosigmoiditis" ], "interventions": [ { "name": "Budesonide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2009-11-17", "completion_date": "2013-04-29", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-07-24T13:30:11.975Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "National City", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008410" } ] }